A privately held company, building a public-health category.
Xandar Kardian Inc. is a Delaware corporation, privately held, headquartered in Toronto. Two doors: one for the shareholders who already back us, one for investors who would like to.

One clearance since 2021, carried into every market we sell in.
FDA 510(k) K202464, with registrations in Canada, Australia, Singapore and Thailand, and an ISO 13485 quality system audited under MDSAP.

An independently certified outcome, rare in the category.
The Validation Institute certified in 2024 that the readings preceded 75.6% of hospital transfers in a 201-patient study. More than 49,000 people monitored to date.

From the ward to the home, and to individuals.
The XK300 Essence for home care and remote patient monitoring, the Kardian consumer line at kardian.com, and a heart-failure research programme with cardiology centres in three jurisdictions.
Backed by specialist investors.
Our investors include Phoenix Venture Partners, Portfolia Active Aging & Longevity Fund, Taronga Ventures and Saltagen Ventures, among others. The Series A round was led by Phoenix, Portfolia and Taronga.
The board of directors is Sam Yang (Chief Executive Officer), Jason Chiu (Cherrypicks, Saltagen Ventures), Srinivas Rao (Phoenix Venture Partners) and Avi Naidu (Taronga Ventures), supported by a board of advisors from healthcare, real estate and venture finance. Delaware corporation; ISO 13485 quality system audited annually under MDSAP.
Leadership and board
Nothing on this website is an offer to sell, or a solicitation of an offer to buy, any security. Any such offer is made only through definitive documents to eligible investors.


